Advertisement

Topics

Eton's conjunctivitis treatment fails to win FDA nod; shares tumble

12:49 EDT 12 Jul 2019 | Reuters

Eton Pharmaceuticals Inc said on Friday that the U.S. Food and Drug Administration declined to approve its treatment for conjunctivitis, sending its shares tumbling nearly 20 percent in extended trading.

Original Article: Eton's conjunctivitis treatment fails to win FDA nod; shares tumble

NEXT ARTICLE

More From BioPortfolio on "Eton's conjunctivitis treatment fails to win FDA nod; shares tumble"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...